Clinical Trial Update: Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating how CYP2C19 genotype-guided clopidogrel and ticagrelor treatment affects platelet function and metabolomics in coronary artery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Universiti Sains Malaysia | Conditions: Coronary Artery Disease (CAD) | Phase 4 | Status: COMPLETED